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Abstract
Objectives: This study was designed to evaluate the immune status of health care workers against varicella zoster in a uni-
versity hospital in Teheran, Iran, and to compare the history of chickenpox infection with the presence of varicella anti-
bodies in this population. Methods: Serologic testing for varicella was performed for 405 health care workers with dif-
ferent job categories and at different age. The enzyme immunoassay was used for determining IgG antibodies against 
varicella zoster virus Results: A total of 405 health care workers, aged 19–50 years (median: 29 years), were examined. 
Of these, 289 (71.4%) were found to be seropositive. No statistically significant differences were observed between gender, 
age, or occupation, and seropositivity (p = 0.09, 0.75, 0.54. respectively). Statistical analysis revealed that the correlation be-
tween chickenpox history and seropositivity showed a 62.3% sensitivity, 72.4% specificity, 84.9% positive predictive value, 
and 43.5% negative predictive value. Conclusions: Serologic screening of health care workers is essential to determine their 
immunity to varicella, regardless of the age, occupation and history of infection. This population is recommended to be 
considered a target group for future immunization programs in Iran.
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INTRODUCTION
The Varicella-Zoster virus (VZV) is transmitted through 
a person to person contact, inhalation of aerosols, through 
contaminated fluids from vesicular skin lesions caused by 
acute chickenpox, or shingles, or infected respiratory tract 
secretions. Varicella is self-limited in children but may 
lead to serious complications among adolescents, adults 
and immunocompromised patients [1]. 
Varicella is a common childhood disease. Nearly a 100% se-
ropositivity to VZV has been documented in children 
between 11–13 years of age in the USA. An epidemiologi-
cal variation is being reported between the temperate and 
tropical climate countries, with varicella occuring mainly 
among young adults in the tropical regions [2]. 
The general adult seroprevalence rates amount to 81.3% in 
the United Arab Emirates, 100% in Belgium, 96.6% in Is-
rael, 95% in Turkey, 95.5% in Spain, 50% in Sri Lanka, 
and 87.9% in Iran [3–9]. 
Moreover, nosocomial transmission of VZV is also re-
ported in health care workers (HCWs) [10]. It seems that 
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March 2009. Serologic testing for varicella was performed 
in 405 HCWs with different job categories (physicians, 
nurses, nurse’s aides, medical and nursing students, and 
administrative workers ) who worked at Rasoul-e-Akram 
hospital, Teheran, Iran. 
A checklist was completed including demographic data 
and the history of varicella. Individuals with acute varicel-
la infection, those under immunosuppressive therapy, or 
those having blood transfusion during the year 2008, were 
excluded from the study. The local ethics committee ap-
proved the study protocol, and a signed informed consent 
was obtained from each participant. 
Blood samples were collected from each individual 
and the separated serum was stored at –20°C prior to 
testing.  EIA  for  varicella-specific  IgG  was  performed 
using  commercial  virus-specific  IgG  EIA  kits  (vari-
cella IgG EIA well, RADIM, Italy; sensitivity 100%, 
specificity  88%).  Optical  density  values  were  indexed 
according to the manufacturer’s instructions. Sera were 
classified  as  negative  if  the OD was  less  than  0.20  and 
as positive if it was higher than 0.70; sera with OD be-
tween 0.20 and 0.70 were considered equivocal. Equivo-
cal values were considered negative. 
Statistical analysis was performed using the SPSS 13 soft-
ware. After conducting descriptive statistical analyses, we 
used the chi square test to study the differences in the 
proportions of the categorical variables between the study 
groups. The P value of less than 0.05 was considered sta-
tistically significant. We compared the history of varicella 
infection in HCWs with the results of testing for antibody 
against varicella zoster antigen to assess the reliability 
of the history of varicella in this population. Sensitivity, 
specificity,  positive  predictive  value  (PPV)  and  negative 
predictive value (NPV) were calculated. In this study, sen-
sitivity refers to the percentage of persons with a history 
of varicella among seropositive HCWs,  specificity  to  the 
percentage of persons without a history of varicella among 
seronegative HCWs, PPV to the percentage of seroposi-
tives among HCWs with a positive history, and NPV to the 
percentage of seronegatives among HCWs with a negative 
history of varicella.
age  alone  is  not  sufficient  to  guarantee  immunity.  The 
community at risk must have a clear history of previous 
varicella infections or a serologic testing. As a small pro-
portion of the population with a history of the disease 
might be susceptible, some experts recommend the se-
rologic testing in all HCWs regardless of the disease his-
tory [11]. 
In a study performed in two neonatal units in Brazil, 150 
of 215 (70%) workers had a history of varicella infec-
tion and all of them had VZ antibodies, which yielded 
a 100% sensitivity of the varicella history. Of the remain-
ing 65 work ers who did not remember having had varicella 
in the past, 60 (92%) proved to have serologic evidence 
of varicella infection, and 5 individuals were considered 
non-immune to varicella. The Brazilian authors have con-
cluded that the positive history of varicella infection is 
a reliable evidence of immunity against the disease [12]. 
In a Japanese study, 97.2% of HCWs in a Tokyo hospi-
tal were immune against varicella but the authors sug-
gested that aggressive screening and vaccination of sus-
ceptible HCWs were essential because most of the Japa-
nese HCWs seemed to have little knowledge about their 
history of VZV infection [13]. 
Varicella history was not a reliable predictor of the pres-
ence or absence of varicella antibodies in HCWs in Sau-
di Arabia. Almuneef and colleagues showed that 84% 
of HCWs in a hospital were seropositive, and the positive 
predictive value (PPV) of the history of chickenpox for 
the seropositivity was 89%. The negative predictive value 
(NPV) was 22% [14].
As no report on varicella zoster virus immunity in HCWs 
in Iran is available, this study has been designed to investi-
gate the seropositivity of VZV among HCWs in a 625-bed 
university hospital. In this study, we aimed at determining 
the relationship between immunity and the history of va-
ricella infection.
METHODS
This cross-sectional, prevalence study was designed to 
investigate the seropositivity of VZV among HCWs 
in a 625-bed university hospital between February and 
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DISCUSSION
Nowadays, the nosocomial transmission of varicella is well 
recognized. Although all susceptible hospitalized adults 
are at risk, certain patients, such as immunocompromised 
persons and pregnant women are at increased risk for 
a severe complicated infection [9]. 
Iran is a country in the tropical area. Here, the seropos-
itivity rate against varicella zoster antigen was reported 
to be about 35% to 60% in children below 10 years to 
nearly 90% in individuals at the age of 30 years [9,15]. 
In our study, 405 HCWs were tested to determine the 
immunity against VZV, and 71.4% of them were found 
RESULTS 
According to the demographic data and serologic test re-
sults of the HCWs (Table 1), 405 HCWs were tested for anti 
varicella IgG. Their age ranged from 19 to 50 years (me-
dian 29 years). Of these workers, 289 (71.4%) were positive 
but we did not find any significant correlation of the gender, 
age, or occupation and seropositivity (p = 0.09, 0.75, 0.54, 
respectively). There was no significant difference between 
the presence of VZV and age (p = 0.75).
Table 2 presents the results regarding the sensitivity, speci-
ficity, positive predictive value and negative predictive val-
ue of the history of varicella for the seropositivity. 
Table 1. Demographic data and serologic results for 405 health care workers studied







female 235 (58.0) 160 (68.1)1 75 (31.9)
male 170 (42.0) 129 (75.9) 1 41 (24.1)
Age (year) 0.75
≤ 25 136 (33.5) 95 (69.8) 41 (30.2)
26–30 103 (25.4) 74 (71.8) 29 (28.2)
31–35 1 58 (14.3) 40 (68.9) 18 (31.1)
≥ 36 108 (26.8) 80 (74.0) 28 (26.0)
Occupation 0.54
nurse 1 78 (19.2) 55 (70.5) 23 (29.5)
nurse’s aide 106 (26.1) 78 (73.6) 28 (26.4)
physician 1 42 (10.3) 35 (83.3) 1 7 (16.7)
medical student 83 (20.4) 59 (71.0) 24 (28.9)
nursing student 33 (8.1) 22 (66.7) 11 (33.3)
administrative worker 63 (15.5) 41 (65.1) 22 (34.9)
Table 2. Varicella antibodies in two groups with and without a history of varicella, and sensitivity analysis
Hx.1 of varicella
Ab titer
total (n) positiven (%)
negative
n (%) PPV NPV sensitivity specificity
Positive Hx. 212 180 (84.9) 32 (15.1) 84.9 43.5 62.3 72.4
Negative Hx.2 193 109 (56.5) 84 (43.5)
1 History.
2 Including uncertain Hx.
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varicella antibody status in HCWs. Indeed, a positive 
history of chickenpox better correlated with the pres-
ence of antibody than did a negative serologic test re-
sult for varicella [14,23,25]. In the populations of Brazil 
and Turkey, and the child population of Switzerland, 
the positive predictive value of the clinical history of 
varicella ranged from 95% to 100% [16,31–33]. In the 
applicants for nurse training in Scotland, the positive 
predictive value of the history of varicella for seroposi-
tivity was 98%. The negative predictive value was 14%. 
A positive history of chickenpox showed a sensitivity 
of 84% and specificity of 60%. The authors concluded 
that the absence of the chickenpox infection in the pa-
tient’s past medical history is an unreliable predictor 
of susceptibility to infection in HCWs [34].
The low PPV in our study might be due to the lack of 
data regarding the past history of viral infections like 
varicella, and the subclinical diseases. The higher NPV 
in our study (43.5%), which is not consistent with oth-
er reports, may reflect a lower general seroprevalence 
in the Iranian HCWs [14,34].
In conclusion, we suggest that, before any decision is 
made to start mass vaccination against VZV in Iran, 
it is necessary to conduct further large-scale studies 
on seroepidemiology of varicella in different popula-
tions (including immunocompromised patients, wom-
en of childbearing age, HCWs, children from different 
age groups,  etc.). The findings of our  study,  showing 
a weak correlation between the clinical history and 
seropositivity, indicate that the serologic screening of 
all HCWs should be recommended. The limitations 
of our study include a small population size and the 
failure to determine which HCWs come from which 
province of Iran. 
ACKNOWLEDGEMENTS
The authors thank Dr. Leila Zahedi-Shoolami, Dr. Tahereh 
Mousavi, and Ms. Yeganeh Shoaee for their assistance. This 
study was supported by the Deputy Research, Iran University of 
Medical Sciences, Teheran, Iran (Grant No. 499).
to  be  seropositive.  In  fact,  a  significant  proportion 
of HCWs are susceptible to varicella. This is important 
in view of their close contact with pregnant women and 
high risk patients whereby the virus can be easily trans-
mitted. 
The results of a recent study regarding seropositiv-
ity  differ  from  the  findings  of  other  studies.  In  Tur-
key, 98% of 363 HCWs had antibodies against varicel-
la [16]. The immunity rates for varicella among medi-
cal students in Germany and Switzerland were 96.9% 
and 97%, respectively, [17,18], while in our study, 
only 71% of medical students were immune. In Israel, 
the seroprevalence of VZ among the HCWs in three 
studies was 94.8%, 94.4% and 98.5% [19–21]. In Japan 
and Brazil, the seropositivity for VZ among HCWs 
ranged from 97.2% to 99.1% [13,22,23]. The seroposi-
tivity rate in the population of 1106 HCWs was 91% 
in North Italy [24] and 93.1% in Canada [25]. In Saudi 
Arabia, the seropositivity amounted to 83%, which 
was less than in the other countries studied [26]. Alto-
gether, these data indicate that there is a difference in 
the immunity against VZV among HCWs in the coun-
tries of the temperate and tropical climatic zones. 
In our study, we found a susceptibility rate of 31.9% 
among 235 women of childbearing age (20–40 years). 
This rate is higher than in Finland (seronegativi-
ty 3.8%) [27], Ireland (seronegativity 11.3%) [28], Italy 
(seronegativity 20%) [29], and lower than in Sri Lanka 
(seronegativity 56.2%) [30]. Therefore, the chance of 
acquiring and transmitting varicella to, or from, the 
patients among our female HCWs is much higher than 
in  other  countries.  Thus,  the  findings  of  the  present 
study indicate the importance of the screening test and 
vaccination for susceptible HCWs in order to reduce 
the rate of varicella in this high risk group.
On the other hand, we compared the history of varicel-
la in HCWs with the results of testing for VZ antibod-
ies to assess the reliability of the history of varicella in 
this group. These data are fundamental to analyze the 
cost effectiveness of different vaccination strategies in 
Iran. Like in other studies, our data showed that the 
history of varicella was not a reliable predictor of the 
VARICELLA ZOSTER IMMUNITY AMONG HEALTH CARE WORKERS      O R I G I N A L  P A P E R S
IJOMEH 2010;23(1) 31
11.  Tennenberg AM, Brassard JE, Lieu J, Drusin LM. Varicella 
vaccination for healthcare workers at a university hospital: an 
analysis of costs and benefits. Infect Control Hosp Epidemi-
ol 1997;18:405–11.
12.  Santos AM, Ono E, Weckx LY, Coutinho AP, de Moraes-
Pinto MI. Varicella zoster antibodies in healthcare workers 
from two neonatal units in Sao Paulo, Brazil — assessment of 
a staff varicella policy. J Hosp Infect 2004;56(3):228–31.
13.  Hatakeyama S, Moriya K, Itoyama S, Nukui Y, Uchida M, 
Shintani Y, et al. Prevalence of measles, rubella, mumps and 
varicella antibodies among healthcare workers in Japan. Infect 
Control Hosp Epidemiol 2004;25(7):591–4.
14.  Almuneef M, Memish ZA, Abbas ME, Balkhy HH. Screening 
healthcare workers for varicella-zoster virus: Can we trust the 
history? Infect Control Hosp Epidemiol 2004;25(7):595–8.
15.  Motamedifar M, Handjani F, Hadi N, Shahkarami MK, 
Mehrabani D. Seroprevalence of Varicella-Zoster Virus in chil-
dren from Shiraz, Iran. Iran J Immunol 2006;3:43–6. 
16.  Celikbas A, Ergonul O, Aksaray S, Tuygun N, Esener H, 
Tanir G, et al. Measles, rubella, mumps, and varicella seroprev-
alence among health care workers in Turkey: Is prevaccination 
screening cost-effective? Am J Infect Control 2006;34(9):583–7.
17.  Wicker S, Rabenau HF, Gottschalk R, Doerr HW, All-
winn R. Seroprevalence of vaccine preventable and blood-
transmissible viral infections (measles, mumps, rubella, polio, 
HBV, HCV and HIV) in medical students. Med Microbiol Im-
munol 2007;196(3):145–50.
18.  Baer G, Bonhoeffer J, Schaad UB, Heininger U. Seropreva-
lence and immunization history of selected vaccine preventable 
diseases in medical students. Vaccine 2005;23(16):2016–20.
19.  Chodick G, Ashkenazi S, Livni G, Lerman Y. Increased 
susceptibility to varicella-zoster virus among Israeli physi-
cians and nurses born in the Middle-East region. J Occup 
Health 2006;48(4):246–52.
20.  Lerman Y, Chodick G, Tepper S, Livni G, Ashkenazi S. 
Seroepidemiology of varicella-zoster virus antibodies among 
health-care workers and day-care centre workers. Epidemiol 
Infect 2004;132(6):1135–8. 
21.  Chazan B, Colodner R, Teitler N, Chen Y, Raz R. Varicella 
zoster virus in health care workers in northern Israel: Seroprev-
alence and predictive value of history of varicella infection. Am 
J Infect Control 2008;36(6):436–8.
REFERENCES
1.  Centers for disease control and prevention. Prevention of 
varicella: Recommendation of the Advisory Committee on 
Immunization Practices (ACIP). MMWR 2007;56(RR-4): 
1–40.
2.  Merrett P, Schwartzman K, Rivest P, Greenaway C. Strate-
gies to prevent varicella among newly arrived adult immi-
grants and refugees: A cost-effectiveness analysis. Clin Infect 
Dis 2007;44:1040–8.
3.  Uduman SA, Tahira AM, AL-Wash R, Usmani MA, Ben-
er A. Varicella susceptibility among children and healthy adults 
in the United Arab Emirates. East Mediterr Health J 2001;7 
(4–5):604–8.
4.  Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, 
Wielen MV, et al. The seroepidemiology of primary varicel-
la-zoster virus infection in Flanders (Belgium). Eur J Pe-
diatr 2002;161(11):588–93.
5.  Cohen DI, Davidovici BB, Smetana Z, Balicer RD, Kle-
ment E, Mendelson E, et al. Seroepidemiology of varicella 
zoster in Israel prior to large-scale use of varicella vaccines. In-
fection 2006;34(4):208–13. 
6.  Alp H, Altinkaynak S , Ertekin V, Kilicaslan B , Giirak-
sin A. Seroepidemiology of varicella-zoster virus infection in 
a cosmopolitan city (Erzarum) in the eastern Turkey. Health 
Policy 2005;72(1):119–24.
7.  Salleras L, Dominguez A, Plans P, Costa J, Cardenosa N, 
Torner N, et al. Seroprevalence of varicella zoster virus infec-
tion in child and adult population of Catalonia (Spain). Med 
Microbiol Immunol 2008;197(3):329–33. 
8.  Kurukulasooriya GM, Thevanesam V, Agampodi SB, Abey-
koon AM, Amarasinghe SP, Goonasekara KP. Susceptibilty 
of new entrant university students in Sri Lanka to varicella 
zoster infection. Asia Pac J Public Health 2009 May 1 [cited 
March 26, 2010]. Available from http://www.ncbi.nlm.nih.
gov/pubmed/19411280.
9.  Sharifi Z, Emadi Ghanjin S. The seroepidemiology of varicella 
zoster virus (vzv) in different age groups in Tehran, Iran. Iran 
J Allergy Asthma Immunol 2005;4(2):95–8.
10.  Weber DJ, Rutala WA, Hamilton H. Prevention and control 
of varicella-zoster infections in health care facilities. Infect 
Control Hosp Epidemiol 1996;17:694–705.
O R I G I N A L  P A P E R S       M. TALEBI-TAHER ET AL.
IJOMEH 2010;23(1)32
29.  Alfonsi V, Montomoli E, Manini I, Alberini I, Gentile C, 
Rota Mc et al. Susceptibility to varicella in childbearing age 
women, central Italy: Is there a need for vaccinating this popu-
lation group? Vaccine 2007;25(32):6086–8.
30.  Liyanage NP, Fernando S, Malavige GN, Mallikahewa R, 
Sivayogan S, Jiffry MT, et al. Seroprevalence of varicella zoster 
virus infections in Colombo district , Sri Lanka. Indian J Med 
Sci 2007;61(3):128–34.
31.  Clemens SA, Azevedo T, Fonseca JC, Silva AC, Silvei-
ra TR, Clemens R. Seroepidemiology of varicella in Bra-
zil — Results of a prospective cross-sectional study. J Pediatr 
(Rio J) 1999;75(6):433–41 [in Portuguese]. 
32.  Lafer MM, de Moraes – Pinto MI, Weckx LY. Prevalence 
of IgG varicella zoster virus antibodies in the Kuikuro and Ka-
iabi indigenous communities in Xingu National Park, Brazil, 
before varicella vaccination. Rev Inst Med Trop Sao Pau-
lo 2005;47(3):139–42.
33.  Heininger U, Baer G, Bonhoeffer J, Schaad UB. Reliabil-
ity of varicella history in children and adolescents. Swiss Med 
Wkly 2005;135(17–18):252–5.
34.  Waclawski ER, Stewart M. Susceptibility to varicella-zoster vi-
rus in applicants for nurse training in Scotland. Commun Dis 
Public Health 2002;5(3):240–2.
22.  Shiraishi T, Nakagawa M, Nakagawa Y, Tominaga M, Yoshi-
tani S. Study of the antibodies against measles, rubella, mumps 
and varicella-zoster viruses in sera from the medical staffs. 
Kansenshogaku Zasshi 2005;79(5):322–8 [in Japanese].
23.  Dos Santos AM, Ono E, Lobato RT, do Prado SI, Kopel-
man BI, Cavalcanti CM, et al. Diphtheria, tetanus, and va-
ricella immunity in health care workers in neonatal units. Am 
J Infect Control 2008;36(2):142–7.
24.  Porru S, Campagna M, Arici C, Carta A, Placidi D, Crotti A, 
et al. Susceptibility to varicella-zoster, measles, rosacea and 
mumps among health care workers in a northern Italy hospital. 
G Ital Med Lav Ergon 2007;29(3 Suppl):407–9 [in Italian].
25.  Ratnam S. Varicella susceptibility in a Canadian population. 
Can J Infect Dis 2000;11(5):249–53.
26.  Almuneef M, Dillon J, Abbas MF, Memish Z. Varicella zoster 
virus immunity in multinational health care workers of a Saudi 
Arabian hospital. Am J Infect Control 2003;31(6):375–81.
27.  Alanen A, Kahala K, Vahlberg T, Koskela P, Vainionpää R. 
Seroprevalence , incidence of prenatal infections and reliability 
of maternal history of varicella zoster virus, cytomegalovirus, 
herpes simplex virus and parvovirus B19 infection in south-
western Finland. BJOG 2005;112(1):50–6.
28.  Knowles SJ, Grundy K, Cahill I, Cafferkey MT. Susceptibil-
ity to infectious rash illness in pregnant women from diverse 
geographical regions. Commun Dis Public Health 2004;7(4): 
344–8.
